Nitridergic Modulation of COX-2 Efficacy

Pain is a common unpleasant sensory and emotional experience, in which are frequently used in their treatment the nonsteroidal anti-inflammatory drugs (NSAIDs). A group of agents with antipyretic, analgesic, and anti-inflammatory properties due to the inhibition of cyclooxygenase enzymes (COXs). Among these drugs there are a group of selective inhibitors of COX-2 named coxib that include to parecoxib, celecoxib, rofecoxib and etoricoxib. Pharmacological information on the mechanism of action of coxibs is insufficient to determine the analgesic and anti-inflammatory efficacy of these agents. There are contradictory reports regarding the antinociceptive effects of the various coxibs at the preclinical level as well as the nitridergic modulation of such actions. The objective of the present study was to evaluate the antinociceptive efficacy of parecoxib, rofecoxib, celecoxib, and etoricoxib using the formalin hind paw assay in mice and the possible contribution of the nitridergic system in the efficacy of COX-2 agents. Antinociception was assessed in a murine formalin assay using dose-response curves to coxibs before and after i.p. administration of 5 mg/kg of L-NAME. Coxibs produced dose-dependent analgesia and anti-inflammation. L-NAME administration reduced the analgesic and anti-inflammatory effectiveness of parecoxib, rofecoxib, celecoxib, and etoricoxib. These findings suggest that the effect of these agents, in addition to COX-2 inhibition, would be mediated by other mechanisms, among which nitridergic modulation would be compromised.

[1]  T. von Woedtke,et al.  Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors , 2022, RSC medicinal chemistry.

[2]  A. van Waarde,et al.  Is cyclooxygenase‐1 involved in neuroinflammation? , 2021, Journal of neuroscience research.

[3]  Mennatallah A. Gowayed,et al.  The effective interplay of (non-) selective NSAIDs with neostigmine in animal models of analgesia and inflammation , 2020, BMC Pharmacology and Toxicology.

[4]  Ziyi Guo,et al.  Cardiovascular Biology of Prostanoids and Drug Discovery. , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[5]  H. Miranda,et al.  Involvement of NO in Antinociception of NSAIDS in Murine Formalin Hind Paw Assay , 2020, Drug Research.

[6]  T. Tipple,et al.  L-NAME releases nitric oxide and potentiates subsequent nitroglycerin-mediated vasodilation , 2019, Redox biology.

[7]  W. Abdelzaher,et al.  Efficacy and safety of combined low doses of either diclofenac or celecoxib with gabapentin versus their single high dose in treatment of neuropathic pain in rats. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  J. Entrena,et al.  Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia , 2017, Neuropharmacology.

[9]  Hong Wang,et al.  The Analgesic Effects of Celecoxib on the Formalin-induced Short- and Long-term Inflammatory Pain. , 2017, Pain physician.

[10]  J. McDougall,et al.  Preclinical Assessment of Inflammatory Pain , 2016, CNS neuroscience & therapeutics.

[11]  O. Aragon-Martinez,et al.  Synergism Between Tramadol and Parecoxib in the Orofacial Formalin Test , 2015, Drug development research.

[12]  Yu-Chiao Yang,et al.  Toona sinensis leaf extract has antinociceptive effect comparable with non-steroidal anti-inflammatory agents in mouse writhing test , 2015, BMC Complementary and Alternative Medicine.

[13]  Sheng-Xi Wu,et al.  Synergistic Analgesia of Duloxetine and Celecoxib in the Mouse Formalin Test: A Combination Analysis , 2013, PloS one.

[14]  A. Becker,et al.  Cannabinoid-mediated diversity of antinociceptive efficacy of parecoxib in Wistar and Sprague Dawley rats in the chronic constriction injury model of neuropathic pain , 2013, Naunyn-Schmiedeberg's Archives of Pharmacology.

[15]  R. Rezende,et al.  Endogenous Opioid and Cannabinoid Mechanisms Are Involved in the Analgesic Effects of Celecoxib in the Central Nervous System , 2012, Pharmacology.

[16]  Katsuya Nakamura,et al.  Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor. , 2011, Biochemical pharmacology.

[17]  J. Carvalho,et al.  Anti-inflammatory and analgesic actions of etoricoxib (an NSAID) combined with misoprostol , 2007, Inflammopharmacology.

[18]  E. Romero-Sandoval,et al.  Antinociception and the new COX inhibitors: research approaches and clinical perspectives. , 2006, CNS drug reviews.

[19]  R. Botting,et al.  The involvement of a cyclooxygenase 1 gene-derived protein in the antinociceptive action of paracetamol in mice. , 2006, European journal of pharmacology.

[20]  T. Nishiyama.  Analgesic effects of intrathecally administered celecoxib, a cyclooxygenase‐2 inhibitor, in the tail flick test and the formalin test in rats , 2006, Acta anaesthesiologica Scandinavica.

[21]  H. Miranda,et al.  Analgesic synergism between intrathecal morphine and cyclooxygenase-2 inhibitors in mice , 2005, Pharmacology Biochemistry and Behavior.

[22]  Dinesh Kumar,et al.  Interaction of inducible nitric oxide synthase and cyclooxygenase-2 inhibitors in formalin-induced nociception in mice. , 2004, European journal of pharmacology.

[23]  J. Mitchell,et al.  Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  S. Kulkarni,et al.  Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. , 2004, European journal of pharmacology.

[25]  G. Castañeda-Hernández,et al.  Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test. , 2002, Life sciences.

[26]  H. Miranda,et al.  An Isobolographic Analysis of the Adrenergic Modulation of Diclofenac Antinociception , 2001, Anesthesia and analgesia.

[27]  R Gordon,et al.  Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. , 2001, The Journal of pharmacology and experimental therapeutics.

[28]  P. Colville-Nash,et al.  COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease , 2000, The Lancet.

[29]  H. Chaves,et al.  Heme oxygenase/carbon monoxide-biliverdin pathway may be involved in the antinociceptive activity of etoricoxib, a selective COX-2 inhibitor. , 2011, Pharmacological reports : PR.

[30]  M. Janovský,et al.  Codeine did not increase analgesic efficacy of coxibs in contrast to that of paracetamol or ibuprofen: isobolographic analysis in mice. , 2011, Neuro endocrinology letters.

[31]  J. Mateos.  [Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review]. , 2010, Drugs of today.

[32]  F. Coluzzi,et al.  COX-2 inhibitors: pharmacological data and adverse effects. , 2005, Minerva anestesiologica.

[33]  S. Kulkarni,et al.  Role of cyclooxygenase-2 in lipopolysaccharide-induced hyperalgesia in formalin test. , 2005, Indian journal of experimental biology.

[34]  F. López-Muñoz,et al.  Participation of the serotonin system in rofecoxib-induced antinociception. , 2004, Proceedings of the Western Pharmacology Society.